Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

332.45 +2.39 (+0.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
40 41 Next >
Inflation 2022 – Week In Review
Arguably, the number one concern in 2022 for most investors, consumers, and businesses is inflation. Inflation is rising in the US and globally, and recent reports this week were not good. 
Via Talk Markets
Blue-Chip Bank Earnings, Retail Data Drag Dow Lower
Within the last hour of trading, the S&P 500 and Nasdaq managed to eke out slight gains. All three major indexes fell for the week. 
Via Talk Markets
How Is The Market Feeling About Amgen Inc?
Amgen Inc's (NASDAQ:AMGN) short percent of float has fallen 11.74% since last its last report. The company recently reported that it has 11.40 million shares sold short, which is... 
Via Benzinga
A Look Into Amgen's Price Over Earnings
Right now, Amgen Inc. (NASDAQ:AMGN) share price is at $229.33, after a 0.45% drop. Over the past month, the stock went up by 7.29%, but over the past year, it... 
Via Benzinga
Europe Approves Amgen's KRAS-Targeted Lung Cancer Therapy
The European Commission (EC) has granted conditional marketing authorization to Amgen Inc's (NASDAQ: AMGN) Lumykras (sotorasib), a KRASG12C inhibitor, for... 
Via Benzinga
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market... 
Via Benzinga
Expert Ratings For Amgen
Amgen (NASDAQ:AMGN) has observed the following analyst ratings within the l... 
Via Benzinga
Expert Ratings For Amgen
Within the last quarter, Amgen (NASDAQ:AMGN) has observed the following ana... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
Financial Stocks Could be Positioned to Kick Off the Q4 Earnings Season
The U.S. dollar was rising against the Japanese yen Tuesday morning as foreign investors take notice of the jump in United States Treasury yields. The Japanese yen is now trading... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022
Upgrades According to TD Securities, the prior rating for Canada Goose Holdings Inc (NYSE: 
Via Benzinga
Dogs Of The Dow Performance Does Not Keep Pace In 2021
In this past year, the 'Dogs of the Dow' strategy did not keep pace with either the Dow Jones Index or the S&P 500 Index. The Dow Dogs generated a total return of 16.3% versus 20.8% for the DJIA and... 
Via Talk Markets
Dogs of Major Indices
As we approach the end of 2021, we take a look at the ten Dow stocks that would currently make up the Dogs of the Dow for 2022. 
Via Talk Markets
These 8 Dow Jones Stocks Are Negative For 2021
The Dow Jones Industrial Average is a price-weighted index consisting of 30 stocks. It's one of the oldest and best-known measures of stock market performance. The blue-... 
Via Benzinga
Best Stocks For Wheel Strategy Trades: Use These In 2022
Blue chips companies, high dividend stocks, REITs, and low beta ETFs work well when employing the wheel strategy. 
Via Talk Markets
BAD ETF: The Top “Sin Stock” Holdings in the New Anti-ESG Fund That Debuts Today
There's a new ETF on the block from BAD Investment Company and it seeks to offer investments in sin stocks for interested traders. 
Via InvestorPlace
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level
The FDA has approved Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or... 
Via Benzinga
Synthetic Biology Platform Senti Bio Rides On Omid Farokhzad's SPAC For NASDAQ Debut
Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzad's Dynamics Special Purpose Corp (NASDAQ: DYNS) in a ... 
Via Benzinga
AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma
The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult... 
Via Benzinga
The Week Ahead In Biotech (Dec. 19-25): Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some... 
Via Talk Markets
The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also... 
Via Benzinga
Up More Than 750%, This Stock Just Increased Its Dividend Again
Dividend growth investing is like the gift that keeps on giving. Except it's better than that. It's the gift that keeps giving more... and more... and more. 
Via Talk Markets
Check Out What Whales Are Doing With AMGN
Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
Piclidenoson Takes On Otezla, a $13 Billion Psoriasis Drug
Photo by Hal Gatewood on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
2 Top Dividend Stocks That Just Hiked Their Payouts by 10% or More
And there could be even more increases in the future. 
Via The Motley Fool
5 Dividend Growth Stocks Getting Crushed… Time To Buy?
We have a disconnect between business performance and stock performance. And we have a disconnect between individual stocks and the stock market. These disconnects could lead us to fantastic long-term... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Early Clinical Data Suggest This New Lotion Could Offer Best-In-Class Eczema Treatment and Infection Prevention, According to Hoth Therapeutics
Image Provided By Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022
Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week... 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
40 41 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.